The role of interleukin-8 in the development and progression of prostate cancer

Update:Oct. 25, 2021Total Views:385Total Downloads:188 DownloadMobile

Author: Sheng WANG 1, 2, 3 Xing-Yu XIONG 1, 2, 3 Lu YANG 1, 2, 3

Affiliation: 1. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China 2. Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China 3. West China Medical School, Sichuan University, Chengdu 610041, China

Keywords: Prostate cancer Interleukin-8 Targeted therapy


Reference:Wang S, Xiong XY, Yang L. The role of interleukin-8 in the development and progression of prostate cancer[J]. Yixue Xinzhi Zazhi, 2021, 31(5): 383-389. DOI: 10.12173/j.issn.1004-5511.202107029.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References

Prostate cancer (PCa), as one of the most common malignant tumors in men poses a seri-ous threat to the health of middle-aged and elderly males. At present, PCa presents many challenges in prediction, diagnosis, treatment and prognosis. Although various PCa biomarkers currently in used clin-ically have certain clinical significance, they do not fully meet the clinical needs. Cytokine interleukin-8 (IL-8) may play an important role in the occurrence and development of PCa. This article summarizes the expression of IL-8 in prostate tissue, the signal transduction pathway related to IL-8 and the mech-anism by which it promotes the occurrence and progression of PCa, in order to provide a reference for the diagnosis, treatment and prognosis of PCa.

Please download the PDF version to read the full text: download

1.Guo Y, Zang Y, Lv L, et al. IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-κB pathway in prostate cancer[J]. Mol Med Rep, 2017, 16(6): 9035-9042. DOI: 10.3892/mmr.2017.7747.

2.Culig Z. CXCL8, an underestimated "bad guy" in prostate cancer[J]. Eur Urol, 2013, 64(2): 189-190. DOI: 10.1016/j.eururo.2012.09.024.

3.王晓朦. 蛋白酶激活受体、IL-8在前列腺癌细胞株中表达的意义[D].云南:昆明医科大学, 2014. [Wang XM. Sig-nificance of expression of protease-activated receptor and IL-8 in prostate cancer cell lines[D]. Yunnan: Kunming Medical University, 2014.]

4.Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer[J]. Clin Cancer Res, 2005, 11(11): 4117-4127. DOI: 10.1158/1078-0432.CCR-04-1518.

5.Liu Q, Li A, Tian Y, et al. The CXCL8-CXCR1/2 pathways in cancer[J]. Cytokine Growth Factor Rev, 2016, 31: 61-71. DOI: 10.1016/j.cytogfr.2016.08.002. 

6.Seaton A, Scullin P, Maxwell PJ, et al. Interleukin-8 signaling promotes androgen-independent prolif-eration of prostate cancer cells via induction of androgen receptor expression and activation[J]. Car-cinogenesis, 2008, 29(6): 1148-1156. DOI: 10.1093/carcin/bgn109. 

7.Araki S, Omori Y, Lyn D, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer[J]. Cancer Res, 2007, 67(14): 6854-6862. DOI: 10.1158/0008-5472.CAN-07-1162.

8.Waugh DJ, Wilson C. The interleukin-8 pathway in cancer[J]. Clin Cancer Res, 2008, 14(21): 6735-6741. DOI: 10.1158/1078-0432.CCR-07-4843.

9.Aalinkeel R, Nair MP, Sufrin G, et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells[J]. Cancer Res, 2004, 64(15): 5311-5321. DOI: 10.1158/0008-5472.CAN-2506-2.

10.Ma F, Wang Z, Abdularab A, et al. Matrix metalloproteinase 9 and prostate cancer risk: a me-ta-analysis of 1059 participants[J]. Minerva Urol Nefrol, 2017, 69(4): 324-329. DOI: 10.23736/S0393-2249.16.02623-0. 

11.Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer[J]. Clin Cancer Res, 2000, 6(5): 2104-2119. 

12.Fujita Y, Okamoto M, Goda H, et al. Prognostic significance of interleukin-8 and CD163-positive cell infiltration in tumor tissues in patients with oral squamous cell carcinoma[J]. PLoS One, 2014, 9(12): e110378. DOI: 10.1371/journal.pone.0110378.

13.Punyani SR, Sathawane RS. Salivary level of interleukin-8 in oral precancer and oral squamous cell car-cinoma[J]. Clin Oral Investig, 2013, 17(2): 517-524. DOI: 10.1007/s00784-012-0723-3.

14.Herrero AB, García-Gómez A, Garayoa M, et al. Effects of IL-8 up-regulation on cell survival and osteo-clastogenesis in multiple myeloma[J]. Am J Pathol, 2016, 186(8): 2171-2182. DOI: 10.1016/j.ajpath.2016.04.003.

15.Perbellini O, Cioffi F, Malpeli G, et al. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6): 1897-1900. DOI: 10.3109/10428194.2014.977889.

16.Yao C, Lin Y , Chua MS, et al. Interleukin-8 modulates growth and invasiveness of estrogen recep-tor-negative breast cancer cells[J]. Int J Cancer, 2007, 121(9): 1949-1957.  DOI: 10.1002/ijc.22930.

17.Singh RK, Lokeshwar BL. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemothera-peutic drugs[J]. Mol Cancer, 2009, 8: 57. DOI: 10.1186/1476-4598-8-57.

18.Shrimali D, Shanmugam MK, Kumar AP, et al. Targeted abrogation of diverse signal trans-duction cascades by emodin for the treatment of inflammatory disorders and cancer[J]. Cancer Lett, 2013, 341(2): 139-149. DOI: 10.1016/j.canlet.2013.08.023.

19.Shorning BY, Dass MS, Smalley MJ, et al. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling[J]. Int J Mol Sci, 2020, 21(12): 4507. DOI: 10.3390/ijms21124507. 

20.Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer[J]. J Biol Chem, 2004, 279(8): 7119-7130. DOI: 10.1074/jbc.M307649200.

21.Weber MJ, Gioeli D, et al. Ras signalling in prostate cancer progression[J]. J Cell Biochem, 2004, 91(1): 13-25. DOI: 10.1002/jcb.10683.

22.MacManus CF, Pettigrew J, Seaton A, et al. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells[J]. Mol Cancer Res, 2007, 5(7): 737-748. DOI: 10.1158/1541-7786.MC R-07-0032.

23.Park S, Kang M, Kim S, et al. α-Actinin-4 promotes the progression of prostate cancer through the Akt/GSK-3β/β-Catenin signaling pathway[J]. Front Cell Dev Biol, 2020, 8: 588544. DOI: 10.3389/fcell.2020.588544. 

24.Sun Y, Ai JZ, Jin X, et al. IL-8 protects prostate cancer cells from GSK-3β-induced oxidative stress by activating the mTOR signaling pathway[J]. Prostate, 2019, 79(10): 1180-1190. DOI: 10.1002/pros.23836.

25.Veltri RW, Miller MC, Zhao G, et al. Interleukin-8 serum levels in patients with benign prostatic hyper-plasia and prostate cancer[J]. Urology, 1999, 53(1): 139-147. DOI: 10.1016/s0090-4295(98)00455-5.

26.Taheri M, Noroozi R, Dehghan A, et al. Interleukin (IL)-8 polymorphisms and risk of prostate disor-ders[J]. Gene, 2019, 692: 22-25. DOI: 10.1016/j.gene.2019.01.005. 

27.Caruso DJ, Carmack AJ, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence[J]. Clin Cancer Res, 2008, 14(13): 4111-4118. DOI: 10.1158/1078-0432.CCR-08-0738.

28.Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival[J]. Prostate, 2014, 74(8): 820-828. DOI: 10.1002/pros.22788.

29.Mian BM, Dinney CP, Bermejo CE, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopicbladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-nB[J]. Clin Cancer Res, 2003, 9(8): 3167-3175. DOI: 10.1093/carcin/bgg106.

30.Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma[J]. Am J Pathol, 2002, 161(1): 125-134. DOI: 10.1016/S0002-9440(10)64164-8.

31.Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposomeencapsu-lated small interfering RNA on ovarian cancer cell growth[J]. J Natl Cancer Inst, 2008, 100(5): 359-372. DOI: 10.1093/jnci/djn024.

Hot Papers